TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Joseph E Levitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.